

MIDER

Omnipod 5: an audit of the first three months of real-world data in an adult insulin pump service

Item Type	Conference Output
Authors	Jesson, AMR;Sears, NL;Kalaiah, Y;Saraf, S
Citation	Jesson, A., Sears, N.S. Saraf, S. and Kalaiah, Y. (2024) 'Omnipod 5: an audit of the first three months of real-world data in an adult insulin pump service'. Diabetes UK Professional Conference. London; 17-19 April.
Publisher	University Hospitals Birmingham NHS Foundation Trust
Rights	Attribution-NonCommercial-NoDerivatives 4.0 International
Download date	2026-04-11 12:07:43
Item License	http://creativecommons.org/licenses/by-nc-nd/4.0/
Link to Item	https://mider.dspace7.openrepository.com/handle/20.500.14200/9365

P255 Omnipod 5: An audit of the first three months of real-world data in an adult insulin pump service

AMR Jesson*, diabetes specialist nurse; NL Sears, diabetes specialist dietitian; Y Kalaiah, consultant physician and S Saraf, consultant physician.

Good Hope Hospital adult insulin pump team, University Hospitals Birmingham, Birmingham, UK


Introduction

Omnipod 5 launched in the UK on 21st June 2023. It is the first insulin patch pump to deliver insulin in a hybrid closed loop. In our pump service, we had 26 patients who have been on Omnipod 5 in a hybrid closed loop with Dexcom G6 for 3 months. This abstract shows our results and experiences from the first 26 patients to use this new and exciting technology.


Method

All patients who had funding for Omnipod insulin pump (Dash or Eros) and qualified for an Omnipod promise upgrade were started on an Omnipod 5 in July/August 2023. All patients have been requested to have an HbA1c checked before the Omnipod 5 start, and at 3 months post Omnipod 5 start. Data has also been used from Glooko, as this data set is complete.


Results



Results



In the first 3 months of Omnipod 5 use in an insulin pump user population, glycaemic control has improved on average by 7.4mmol mol⁻¹. Hypoglycaemic events have reduced to less than 1% of time in target range. All patients switched to Omnipod 5 have the same or more time in target range (3.9-10mmol mol⁻¹), with the best change in time in target range a 46% increase (28% to 74% time in target). 25 of 26 patients have less time in the hypoglycaemia range, with average time in hypoglycaemic range now less than 1% (1.95% reduced to 0.96%).



Summary

The new hybrid closed loop patch pump, Omnipod 5, shows improvement in HbA1c and less time in hypoglycaemia. Patients report improved quality of life; better sleep; less worry and are more engaged to improve their glycaemic control further.